The global chronic Granulomatous disease (CGD) management market is expected to garner a market value of US$ 1.31 Billion in 2023 and is expected to accumulate a market value of US$ 2.11 Billion by registering a CAGR of 4.9% in the forecast period 2023 to 2033. Growth of the chronic Granulomatous disease (CGD) management market can be attributed to increasing research and development activities by key players for developing medications. the market for chronic Granulomatous disease (CGD) management registered a CAGR of 3.3% in the historical period 2018 to 2022.
The chronic granulomatous disease is a severe genetic condition that is passed down through the generations. People who suffer from this disease have weakened immune systems, making them subject to chronic inflammation and bacterial and fungal infections. The signs and symptoms of this condition appear in infancy or early childhood.
Report Attribute | Details |
---|---|
Expected Market Value (2023) | US$ 1.31 Billion |
Anticipated Forecast Value (2033) | US$ 2.11 Billion |
Projected Growth Rate (2023 to 2033) | 4.9% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Chronic Granulomatous disease (CGD) management reflected a value of 3.3% during the historical period, 2018 to 2022.
Chronic granulomatous disease or CGD is a kind of disorder under which white blood cells (phagocytes) are unable to kill certain types of bacteria and fungi. It is basically an inherited primary immunodeficiency disease caused by defects in the NADPH oxidase complex resulting in respiratory bursts in phagocytic leukocytes. The patients might develop skin infections, lymph node infections, pneumonia, lung infections, liver infections, gastrointestinal inflammation, or other infections. Thus, with the unique nature of CGD, the development of medications has increased rapidly. In the upcoming years, technological integration and research will boost the market for CGD management market.
Thus, the market for Chronic Granulomatous disease (CGD) management is expected to register a CAGR of 4.9% in the forecast period 2023 to 2033.
Research and development activities boosting the growth of the CGD market
The fact that 1 in 200000 or 250000 people suffer from CGD makes it a rare disease. In addition, the signs and symptoms of this illness differ from person to person. Frequent bacterial and fungal infections, swollen lymph nodes, recurrent diarrhoea, and abscesses involving the liver, lungs, spleen, bones, or skin are some of the most prevalent signs and symptoms.
The market is expected to rise due to factors such as the rising prevalence of rare illnesses, increased healthcare spending in developed economies, and increased research and development activities.
Changing lifestyles along with advancements in technology to innovate medication accelerating market growth
Factors such as the changes adopted in lifestyle and alterations in food habits is further expected to accelerate the overall growth of the chronic granulomatous disease treatment market within the forecast period. Additionally, the growing prevalence of rare diseases in some developing countries and increasing research and development activities boost the overall market’s demand.
Additionally, the advancement in technology and rising government funding for the healthcare sector are to further extend suitable opportunities for the growth of the chronic granulomatous disease treatment market in the near future.
Expensive nature of the treatment along with the lack of awareness hampering the market growth
The unavailability of effective treatments for different types of chronic granulomatous disease along with the high cost associated with treatment and diagnostic tests of chronic granulomatous disease is anticipated to most likely obstruct the growth of the chronic granulomatous disease treatment market in the coming years.
The lack of awareness about the disease in developing and underdeveloped economies can be one of the challenging factors within the forecast period. For example, Genetic testing might cost anything from $100 to $2,000. All these factors are hampering the growth of the CGD market.
Research and development activities create lucrative opportunities for market growth
The North American region is expected to hold the largest market share for the CGD market. This is due to a well-developed healthcare sector, the rising prevalence of rare diseases, the steadily growing occurrence of chronic granulomatous disease (CGD), and a relatively large number of research and development activities in the North American region.
According to a 2017 report published by the National Center for Biotechnology Information (NCBI), CGD affects 1 in 200,000 to 1 in 250,000 births in the United States. This, in turn, has created lucrative opportunities for innovating medication for treating the ailment. Furthermore, increased government support for the healthcare sector in the region is another factor driving the growth of the market. Thus, the North American region is expected to dominate the Chronic Granulomatous Disease by possessing a 45% market share in 2023.
Development of the healthcare sector shaping the landscape for the CGD market
The rising prevalence of rare diseases, as well as increased research and development activities, are driving market growth in this region. According to Eurostat, gross domestic expenditure (GERD) on research and development was EUR 303 billion in 2016.
In addition, increasing government funding for the healthcare sector and increasing research and development activities are changing the landscape for the CGD market. With the strong presence of key players in the region, Europe is expected to hold a 35% market share in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Detection of symptoms in early age advancing growth of X-linked CGD
Based on the Type, the market is segmented into X-Linked Chronic Granulomatous Disease and Autosomal Recessive Chronic Granulomatous Disease.
Patients with X-linked CGD often develop infections in their first ten years of life, and around 40% of them die before they reach the age of 35. Males are more likely than females to develop the chronic granulomatous disease. Approximately two-thirds of people in North American and European research had the X-linked recessive type of the disease. CGD is present at birth because it is a hereditary condition.
CGD symptoms normally appear throughout childhood or early adolescence, but they can sometimes be delayed until the early adolescent years. The earliest symptoms have been found to appear in adults in a few cases. The chronic granulomatous disease affects approximately four to five people in every Billion people globally.
Thus, the X-Linked Chronic Granulomatous Disease segment is expected to possess 52% market for the CGD market in 2023.
Trimethoprim exhibiting promising results for treating CBD
Based on the Treatment, the market is segmented into Infection Management, Trimethoprim, Sulfamethoxazole, Itraconazole, Interferon-gamma, Stem cell transplantation, and others. Trimethoprim is expected to hold the largest share of the CGD market in 2023.
Continuous antibiotic medication to help prevent infections, such as trimethoprim for bacterial infections and itraconazole for fungal infections, is used to treat chronic granulomatous illness. Antibiotics are usually required for infections. Corticosteroid medications can also help with granulomatous consequences. In some people with CGD, bone marrow transplants have been shown to be beneficial.
Thus, Trimethoprim is expected to possess a 40% market share for the CGD market in 2023.
Hospitals increasing accessibility for treatment of CBD management market
Based on the end-user, the market is segmented into Hospitals, Clinical laboratories, and Others. The hospital segment is expected to hold the largest market share in 2023.
This is due to the growing number of Chronic Granulomatous Disease patients increasing the treatments of Chronic Granulomatous Disease in hospitals. Hospitals are a significant part of the healthcare industry and a key source of revenue for the overall industry, which stimulates research and innovation.
As a result, a number of firms devote large resources to promoting their products and services among hospitals, both in terms of revenue and marketing tactics. Due to these factors, strategic decisions made in the hospital sector can have an impact on other sectors of the healthcare industry, providing them significant control over contract conditions with suppliers, service providers, and distributors.
These are the key factors that are expected to drive the growth of the hospital segment in the Chronic Granulomatous Disease Market during the forecast period. Thus, hospitals are expected to possess a 40% market share in the CBD management market.
Key players in the chronic Granulomatous disease (CGD) management market are Clinigen Group plc, Orchard Therapeutics plc, Horizon Therapeutics plc, ViroMed. Co. Ltd, Bellicum Pharmaceuticals, Inc, Pfizer Inc, Hoffmann-La Roche Ltd, Novartis AG, Lonza, GlaxoSmithKline plc, Eli Lilly and Company, Johnson & Johnson Services, Inc, Merck KGaA
Report Attribute | Details |
---|---|
Market Value in 2023 | US$ 1.31 Billion |
Market Value in 2033 | US$ 2.11 Billion |
Growth Rate | CAGR of 4.9% from 2023 to 2033 |
Base Year for Estimation | 2022 |
Historical Data | 2018 to 2022 |
Forecast Period | 2023 to 2033 |
Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Customization | Available Upon Request |
The industry will reach a market value of US$ 1.31 billion in 2023.
The market witnessed 3.3% historically.
North America is likely to generate 45% revenue in 2023.
Europe's market size is expected to hold a 35% share in 2023.
The market is expected to record a 4.9% CAGR until 2033.
1. Executive Summary | Chronic Granulomatous Disease (CGD) Management Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
5.3.1. X-Linked Chronic Granulomatous Disease
5.3.2. Autosomal Recessive Chronic Granulomatous Disease
5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033
6.3.1. Neutrophil Function Tests
6.3.2. Genetic Testing
6.3.3. Prenatal Testing
6.3.4. Others
6.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033
7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
7.3.1. Infection Management
7.3.2. Trimethoprim
7.3.3. Sulfamethoxazole
7.3.4. Itraconazole
7.3.5. Interferon-gamma
7.3.6. Stem Cell Transplantation
7.3.7. Others
7.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By End-User, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User, 2023 to 2033
8.3.1. Hospitals
8.3.2. Clinical Laboratory
8.3.3. Homecare
8.3.4. Others
8.4. Y-o-Y Growth Trend Analysis By End-User, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By End-User, 2023 to 2033
9. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. Middle East & Africa (MEA)
9.4. Market Attractiveness Analysis By Region
10. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. USA
10.2.1.2. Canada
10.2.2. By Type
10.2.3. By Diagnosis
10.2.4. By Treatment
10.2.5. By End-User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. By Diagnosis
10.3.4. By Treatment
10.3.5. By End-User
10.4. Key Takeaways
11. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Type
11.2.3. By Diagnosis
11.2.4. By Treatment
11.2.5. By End-User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. By Diagnosis
11.3.4. By Treatment
11.3.5. By End-User
11.4. Key Takeaways
12. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. US
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Type
12.2.3. By Diagnosis
12.2.4. By Treatment
12.2.5. By End-User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. By Diagnosis
12.3.4. By Treatment
12.3.5. By End-User
12.4. Key Takeaways
13. South Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Type
13.2.3. By Diagnosis
13.2.4. By Treatment
13.2.5. By End-User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Type
13.3.3. By Diagnosis
13.3.4. By Treatment
13.3.5. By End-User
13.4. Key Takeaways
14. East Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Type
14.2.3. By Diagnosis
14.2.4. By Treatment
14.2.5. By End-User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Type
14.3.3. By Diagnosis
14.3.4. By Treatment
14.3.5. By End-User
14.4. Key Takeaways
15. Oceania Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Type
15.2.3. By Diagnosis
15.2.4. By Treatment
15.2.5. By End-User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Type
15.3.3. By Diagnosis
15.3.4. By Treatment
15.3.5. By End-User
15.4. Key Takeaways
16. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Type
16.2.3. By Diagnosis
16.2.4. By Treatment
16.2.5. By End-User
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Type
16.3.3. By Diagnosis
16.3.4. By Treatment
16.3.5. By End-User
16.4. Key Takeaways
17. Key Countries Analysis
17.1. USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Type
17.1.2.2. By Diagnosis
17.1.2.3. By Treatment
17.1.2.4. By End-User
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Type
17.2.2.2. By Diagnosis
17.2.2.3. By Treatment
17.2.2.4. By End-User
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Type
17.3.2.2. By Diagnosis
17.3.2.3. By Treatment
17.3.2.4. By End-User
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Type
17.4.2.2. By Diagnosis
17.4.2.3. By Treatment
17.4.2.4. By End-User
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Type
17.5.2.2. By Diagnosis
17.5.2.3. By Treatment
17.5.2.4. By End-User
17.6. UK
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Type
17.6.2.2. By Diagnosis
17.6.2.3. By Treatment
17.6.2.4. By End-User
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Type
17.7.2.2. By Diagnosis
17.7.2.3. By Treatment
17.7.2.4. By End-User
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Type
17.8.2.2. By Diagnosis
17.8.2.3. By Treatment
17.8.2.4. By End-User
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Type
17.9.2.2. By Diagnosis
17.9.2.3. By Treatment
17.9.2.4. By End-User
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Type
17.10.2.2. By Diagnosis
17.10.2.3. By Treatment
17.10.2.4. By End-User
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Type
17.11.2.2. By Diagnosis
17.11.2.3. By Treatment
17.11.2.4. By End-User
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Type
17.12.2.2. By Diagnosis
17.12.2.3. By Treatment
17.12.2.4. By End-User
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Type
17.13.2.2. By Diagnosis
17.13.2.3. By Treatment
17.13.2.4. By End-User
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Type
17.14.2.2. By Diagnosis
17.14.2.3. By Treatment
17.14.2.4. By End-User
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Type
17.15.2.2. By Diagnosis
17.15.2.3. By Treatment
17.15.2.4. By End-User
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Type
17.16.2.2. By Diagnosis
17.16.2.3. By Treatment
17.16.2.4. By End-User
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Type
17.17.2.2. By Diagnosis
17.17.2.3. By Treatment
17.17.2.4. By End-User
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Type
17.18.2.2. By Diagnosis
17.18.2.3. By Treatment
17.18.2.4. By End-User
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Type
17.19.2.2. By Diagnosis
17.19.2.3. By Treatment
17.19.2.4. By End-User
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Type
17.20.2.2. By Diagnosis
17.20.2.3. By Treatment
17.20.2.4. By End-User
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Type
17.21.2.2. By Diagnosis
17.21.2.3. By Treatment
17.21.2.4. By End-User
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Type
18.3.3. By Diagnosis
18.3.4. By Treatment
18.3.5. By End-User
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Clinigen Group plc
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Orchard Therapeutics plc2032
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Horizon Therapeutics plc
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. ViroMed. Co. Ltd
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Bellicum Pharmaceuticals, Inc.
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Pfizer Inc.
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. F. Hoffmann-La Roche Ltd
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Novartis AG
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Lonza
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. GlaxoSmithKline plc.
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.11. Eli Lilly and Company
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
19.1.12. Johnson & Johnson Services, Inc.
19.1.12.1. Overview
19.1.12.2. Product Portfolio
19.1.12.3. Profitability by Market Segments
19.1.12.4. Sales Footprint
19.1.12.5. Strategy Overview
19.1.12.5.1. Marketing Strategy
19.1.13. Merck KGaA
19.1.13.1. Overview
19.1.13.2. Product Portfolio
19.1.13.3. Profitability by Market Segments
19.1.13.4. Sales Footprint
19.1.13.5. Strategy Overview
19.1.13.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports